NZ598927A - Antiviral nucleoside analogs - Google Patents

Antiviral nucleoside analogs

Info

Publication number
NZ598927A
NZ598927A NZ598927A NZ59892708A NZ598927A NZ 598927 A NZ598927 A NZ 598927A NZ 598927 A NZ598927 A NZ 598927A NZ 59892708 A NZ59892708 A NZ 59892708A NZ 598927 A NZ598927 A NZ 598927A
Authority
NZ
New Zealand
Prior art keywords
compounds
methyltetrahydrofuran
triazin
hydroxymethyl
diol
Prior art date
Application number
NZ598927A
Other languages
English (en)
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of NZ598927A publication Critical patent/NZ598927A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ598927A 2007-01-12 2008-01-11 Antiviral nucleoside analogs NZ598927A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88027807P 2007-01-12 2007-01-12
PCT/US2008/050929 WO2008089105A2 (en) 2007-01-12 2008-01-11 Antiviral nucleoside analogs

Publications (1)

Publication Number Publication Date
NZ598927A true NZ598927A (en) 2013-09-27

Family

ID=39471795

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ598927A NZ598927A (en) 2007-01-12 2008-01-11 Antiviral nucleoside analogs
NZ578556A NZ578556A (en) 2007-01-12 2008-01-11 Antiviral nucleoside analogs

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ578556A NZ578556A (en) 2007-01-12 2008-01-11 Antiviral nucleoside analogs

Country Status (19)

Country Link
US (1) US8440813B2 (en:Method)
EP (2) EP2535345A1 (en:Method)
JP (1) JP2010515760A (en:Method)
CN (1) CN101611046A (en:Method)
AU (1) AU2008206406A1 (en:Method)
CA (1) CA2674589A1 (en:Method)
CY (1) CY1113282T1 (en:Method)
DK (1) DK2114980T3 (en:Method)
ES (1) ES2390188T3 (en:Method)
HR (1) HRP20120758T1 (en:Method)
IL (1) IL199664A0 (en:Method)
MX (1) MX2009007333A (en:Method)
NZ (2) NZ598927A (en:Method)
PH (1) PH12012502284A1 (en:Method)
PL (1) PL2114980T3 (en:Method)
PT (1) PT2114980E (en:Method)
SG (1) SG177974A1 (en:Method)
SI (1) SI2114980T1 (en:Method)
WO (1) WO2008089105A2 (en:Method)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124759B2 (en) * 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
PL2155758T3 (pl) 2007-05-10 2013-06-28 Biocryst Pharm Inc Pochodne tetrahydrofuro[3,4-d]dioksolanu przeznaczone do stosowania w leczeniu infekcji wirusowych i raka
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
US20090247750A1 (en) * 2008-03-28 2009-10-01 Biocryst Pharmaceuticals, Inc. Process for preparing nucleoside analogs
SI2268642T1 (sl) 2008-04-23 2015-05-29 Gilead Sciences, Inc. 1'-substituirani karba-nukleozidni analogi za antivirusno zdravljenje
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
PL2396340T3 (pl) 2009-02-10 2014-05-30 Gilead Sciences Inc Analogi karba-nukleozydu do terapii przeciwwirusowych
ME02656B (me) * 2009-09-21 2017-06-20 Gilead Sciences Inc 2' -fluoro supstituisani karba-nukleozidni analozi za antiviralno lečenje
WO2011035250A1 (en) * 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
EP2552922A1 (en) 2010-03-31 2013-02-06 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
US9090642B2 (en) 2010-07-19 2015-07-28 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
JP5969471B2 (ja) 2010-07-22 2016-08-17 ギリード・サイエンシズ・インコーポレーテッド パラミクソウイルス科ウイルス感染症を治療するための方法及び化合物
TW201305185A (zh) * 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
PH12013500311B1 (en) 2010-09-20 2017-11-08 Gilead Sciences Inc 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
ES2701020T3 (es) 2010-09-22 2019-02-20 Alios Biopharma Inc Nucleósidos azido y análogos nucleotídicos
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
ES2744587T3 (es) 2011-04-13 2020-02-25 Gilead Sciences Inc Análogos de N-nucleósido de pirimidina 1-sustituidos para un tratamiento antiviral
KR20140036269A (ko) 2011-07-01 2014-03-25 바이엘 인텔렉쳐 프로퍼티 게엠베하 Alk1 억제제로서의 히드록시메틸아릴-치환된 피롤로트리아진
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
CA2752008A1 (en) 2011-09-13 2013-03-13 Universite De Montreal Combination therapy using ribavirin as elf4e inhibitor
UA117095C2 (uk) 2011-12-22 2018-06-25 Аліос Біофарма, Інк. Нуклеозидна сполука або її фармацевтично прийнятна сіль
EP3210993B1 (en) * 2012-03-13 2018-12-12 Gilead Sciences, Inc. 2'- substituted carba-nucleoside analogs for antiviral treatment
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AR090699A1 (es) 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
SI2861595T1 (sl) 2012-06-13 2017-04-26 Incyte Holdings Corporation Substituirane triciklične spojine kot inhibitorji fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
MX2015005949A (es) * 2012-11-16 2015-09-08 Biocryst Pharm Inc Nucleosidos que contienen aza-azucar antiviral.
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
ES2657451T3 (es) 2013-04-19 2018-03-05 Incyte Holdings Corporation Heterocíclicos bicíclicos como inhibidores del FGFR
KR102314960B1 (ko) 2013-10-11 2021-10-19 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 이의 유사체
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
ES2749679T3 (es) 2014-10-22 2020-03-23 Bristol Myers Squibb Co Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10214537B2 (en) 2014-10-22 2019-02-26 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds
TWI740546B (zh) * 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2016229966B2 (en) 2015-03-06 2018-09-27 Atea Pharmaceuticals, Inc. Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
CN104876935B (zh) * 2015-05-18 2017-04-19 南方医科大学 2‑氨基吡咯并[1,2‑f][1,2,4]三嗪类化合物、合成方法及应用
CN114366745A (zh) 2015-09-16 2022-04-19 吉利德科学公司 治疗沙粒病毒科和冠状病毒科病毒感染的方法
US10953029B2 (en) 2015-09-23 2021-03-23 Merck Sharp & Dohme Corp. 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof
CN109071467B (zh) 2016-03-09 2023-04-04 艾丽奥斯生物制药有限公司 无环抗病毒药
EP3426287A4 (en) 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
LT3436461T (lt) 2016-03-28 2024-03-12 Incyte Corporation Pirolotriazino junginiai kaip tam inhibitoriai
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
ES2907874T3 (es) 2016-09-07 2022-04-26 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-sustituidos-N6-sustituidos para el tratamiento de virus de ARN
EP3538108A4 (en) * 2016-11-10 2020-06-17 Oyagen, Inc. METHODS OF TREATING AND INHIBITING EBOLA VIRUS INFECTION
JP7066728B2 (ja) 2017-02-01 2022-05-13 アテア ファーマシューティカルズ， インコーポレイテッド Ｃ型肝炎ウイルスの治療のためのヌクレオチドヘミ硫酸塩
KR102460968B1 (ko) 2017-03-14 2022-11-01 길리애드 사이언시즈, 인코포레이티드 고양이 코로나바이러스 감염의 치료 방법
CN110636884B (zh) 2017-05-01 2022-10-04 吉利德科学公司 新结晶形式
CN107056775A (zh) * 2017-05-24 2017-08-18 佛山科学技术学院 丙型肝炎病毒ns5b聚合酶抑制剂
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
TW201919648A (zh) 2017-07-11 2019-06-01 美商基利科學股份有限公司 用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
WO2019200005A1 (en) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
KR20210018265A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 고체 형태 및 이의 제조 방법
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
KR20210102364A (ko) 2018-12-12 2021-08-19 얀센 바이오파마, 인코퍼레이트. 항바이러스제로서의 사이클로펜틸 뉴클레오시드 유사체
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7675711B2 (ja) 2019-10-14 2025-05-13 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220285A (es) 2019-12-04 2022-10-27 Incyte Corp Derivados de un inhibidor de fgfr
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI789695B (zh) 2020-01-27 2023-01-11 美商基利科學股份有限公司 治療sars cov-2感染之方法
US11738025B2 (en) 2020-02-04 2023-08-29 Oyagen, Inc. Method for treating coronavirus infections
CN113214262B (zh) * 2020-02-05 2023-07-07 华创合成制药股份有限公司 一种含有胍基的化合物及其制备方法和用途
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
CN115135383B (zh) 2020-02-18 2024-06-11 吉利德科学公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
TWI791193B (zh) 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
JP7554841B2 (ja) 2020-03-12 2024-09-20 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
KR102906891B1 (ko) 2020-04-06 2026-01-05 길리애드 사이언시즈, 인코포레이티드 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형
KR20230018473A (ko) 2020-05-29 2023-02-07 길리애드 사이언시즈, 인코포레이티드 렘데시비르 치료 방법
JP2023531524A (ja) 2020-06-24 2023-07-24 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシド類似体及びその使用
EP4183792A4 (en) * 2020-07-14 2024-03-20 Sichuan University NITROGEN-CONTAINING 3-DESOXY-2-KETONE ACID DERIVATIVE, PRODUCTION PROCESS THEREOF AND USE THEREOF
AU2021331214B2 (en) 2020-08-27 2024-01-04 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
MX2024002116A (es) 2021-08-20 2024-03-06 Shionogi & Co Derivados de nucleosido y profarmacos de los mismos que tienen accion inhibidora del crecimiento viral.
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU771776B2 (en) 1999-01-13 2004-04-01 Genentech Inc. Serine protease inhibitors
IL153020A0 (en) * 2000-05-26 2003-06-24 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
WO2003062255A2 (en) * 2002-01-17 2003-07-31 Ribapharm Inc. Sugar modified nucleosides as viral replication inhibitors
US7429565B2 (en) 2003-04-25 2008-09-30 Gilead Sciences, Inc. Antiviral phosphonate analogs
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
EP1814561A4 (en) 2004-10-29 2012-12-19 Biocryst Pharm Inc THEROPUTICAL FUROPYRIMIDINES AND THIENOPYRIMIDINES
TW200942243A (en) * 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
WO2010002877A2 (en) * 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents

Also Published As

Publication number Publication date
NZ578556A (en) 2012-04-27
JP2010515760A (ja) 2010-05-13
PH12012502284A1 (en) 2015-10-12
CN101611046A (zh) 2009-12-23
US20100015094A1 (en) 2010-01-21
MX2009007333A (es) 2009-08-31
PT2114980E (pt) 2012-09-25
US8440813B2 (en) 2013-05-14
ES2390188T3 (es) 2012-11-07
IL199664A0 (en) 2010-04-15
EP2114980A2 (en) 2009-11-11
PL2114980T3 (pl) 2012-11-30
CA2674589A1 (en) 2008-07-24
CY1113282T1 (el) 2016-04-13
DK2114980T3 (da) 2012-09-24
WO2008089105A3 (en) 2008-09-12
HRP20120758T1 (hr) 2012-10-31
WO2008089105A2 (en) 2008-07-24
EP2535345A1 (en) 2012-12-19
SI2114980T1 (sl) 2012-11-30
HK1138286A1 (en) 2010-08-20
AU2008206406A1 (en) 2008-07-24
EP2114980B1 (en) 2012-06-27
SG177974A1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
NZ598927A (en) Antiviral nucleoside analogs
PT2187742T (pt) Derivados de (2s,3r,4r,5s,6r)-2-(4-cloro-3-benzilfenil)-6-(hidroximetil)tetrahidro-2h-piran-3,4,5-triol para utilização no tratamento da diabetes
NL300701I2 (en:Method)
IL225672B (en) Pharmaceutical composition comprising (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol for inhibiting rna viral polymerase
NZ601486A (en) 2',4'-substituted nucleosides as antiviral agents
NZ596301A (en) Novel 7-deazapurine nucleosides for therapeutic uses
RU2651892C3 (ru) Нуклеозидфосфорамидаты в качестве противовирусных агентов
MY150059A (en) Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
GEP20125658B (en) Imidazotriazines and imidazo pyrimidines as kinase inhibitors
GEP20135780B (en) Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer agents
EP1749830A4 (en) CURCUMOL DERIVATIVES, COMPOSITION COMPRISING THE SAME, AND THEIR USE FOR THE PRODUCTION OF MEDICAMENTS
BRPI0910455B8 (pt) análogos de carba-nucleosídeo 1’-substituído para tratamento antiviral e composição farmacêutica que os compreende
NZ606156A (en) Methods and compounds for treating paramyxoviridae virus infections
MX2010003668A (es) Derivados de purina sustituidas con primidina.
TW200637562A (en) Anti-cancer agent containing α-α-α-trifluorothymidine and thymidine phosphorylase inhibitor in combination
MXPA05010293A (es) 4-amino[1,2,4]triazolo[4,3-a]quinoxalinas sustituidas.
EA200800992A1 (ru) 2-амино-7,8-дигидро-6н-пиридо[4,3-d]пиримидин-5-оны, способ их получения, способ терапии с их помощью, компонент композиции и композиция на их основе, 2,4-диоксопиперидиновые соединения для их получения
WO2008070313A3 (en) 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
WO2018160855A1 (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2006124861A3 (en) Benzofuran compounds
WO2014152566A3 (en) Methods of synthesizing substituted purine compounds
WO2006116733A3 (en) Protein kinase inhibitors
WO2006058628A3 (en) Substituted benzoquinolizines as dpp-iv inhibitors for the treatment of diabetes
WO2009034547A3 (en) New 4-substituted derivatives of pyrazolo[3,4-d pyrimidine and pyrrolo[2,3-d]pyrimidine and uses thereof
WO2006083949A3 (en) Sepsis prevention through adenosine receptor modulation

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE MISSING INVENTOR HAS BEEN ADDED (1276945, KOTIAN, PRAVIN L; 1348301, CHAND, POORAN; 1348303, WU, MINWAN; 1348304, KUMAR, V. SATISH; 3043104, BABU, YARLAGADDA, S.)

Effective date: 20131008

PSEA Patent sealed
LAPS Patent lapsed